



Original Research

Diagnostic Performance of a Novel AI-Guided Coronary Computed Tomography Algorithm for Predicting Myocardial Ischemia (AI-QCT_{ISCHEMIA}) Across Sex and Age Subgroups



Putri Annisa Kamila, MD^{a,b,*,†}, Tara Hojjati^{c,†}, Nick S. Nurmohamed, MD, PhD^{d,e}, Ibrahim Danad, MD, PhD^f, Yipu Ding, MD^{a,g}, Ruurt A. Jukema, MD^d, Pieter G. Raijmakers, MD, PhD^h, Roel S. Driessen, MD, PhD^d, Michiel J. Bom, MD, PhD^d, Pepijn van Diemen, MD^d, Gianluca Pontone, MD, PhD^{i,j}, Daniele Andreini, MD, PhD^k, Hyuk-Jae Chang, MD, PhD^l, Richard J. Katz, MD^m, Andrew D. Choi, MD^m, Paul Knaapen, MD, PhD^d, Jeroen J. Bax, MD, PhD^{a,n}, Alexander van Rosendael, MD, PhD^a, for the CREDENCE and PACIFIC-1 Investigators¹

^a Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands; ^b Faculty of Medicine, Universitas Brawijaya, Malang, Indonesia;

^c The College of Liberal Arts and Sciences, Arizona State University, Tempe, Arizona; ^d Department of Cardiology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands; ^e Department of Vascular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands;

^f Department of Cardiology, Radboud University Medical Center, Nijmegen, the Netherlands; ^g School of Medicine, Nankai University, Tianjin, China;

^h Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands; ⁱ Department of Cardiovascular Imaging, Centro Cardiologico Monzino, IRCCS, Milan, Italy; ^j Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy; ^k Department of University Cardiology and Cardiac Imaging, IRCCS Ospedale Galeazzi Sant'Ambrogio, Milan, Italy; ^l Division of Cardiology, Severance Cardiovascular Hospital and Severance Biomedical Science Institute, Yonsei University College of Medicine, Yonsei University Health System, Seoul, South Korea; ^m Division of Cardiology, The George Washington University School of Medicine, Washington, District of Columbia; ⁿ Turku University Hospital and University of Turku, Turku, Finland

ABSTRACT

Background: AI-QCT_{ISCHEMIA} is a novel artificial intelligence algorithm that predicts myocardial ischemia using quantitative features from coronary computed tomography angiography, providing a noninvasive alternative to functional imaging. However, its diagnostic performance across key demographic subgroups, particularly by sex and age, remains underexplored. We aimed to evaluate the diagnostic performance of AI-QCT_{ISCHEMIA} for predicting myocardial ischemia across these subgroups.

Methods: This post-hoc analysis included symptomatic patients with suspected coronary artery disease from the CREDENCE (Computed Tomographic Evaluation of Atherosclerotic Determinants of Myocardial Ischemia) (n = 305; 868 vessels) and PACIFIC-1 (Comparison of Coronary Computed Tomography Angiography, Single Photon Emission Computed Tomography [SPECT], Positron Emission Tomography [PET], and Hybrid Imaging for Diagnosis of Ischemic Heart Disease Determined by Fractional Flow Reserve) (n = 208; 612 vessels) studies. All patients underwent coronary computed tomography angiography, myocardial perfusion imaging (SPECT and/or PET), and invasive coronary angiography with 3-vessel fractional flow reserve as the reference standard. Diagnostic performance was evaluated at the vessel level using receiver operating characteristic analysis and under the curve (AUC), stratified by sex and age groups.

Results: In computed tomographic evaluation of atherosclerotic determinants of myocardial ischemia, AI-QCT_{ISCHEMIA} demonstrated higher diagnostic performance than myocardial perfusion imaging, with AUCs of 0.87 vs 0.63 in men and 0.85 vs 0.71 in women (P < .001 for both). Similarly, in older (≥65 years) and younger (<65 years) patients, AUCs were 0.85 vs 0.67 and 0.87 vs 0.63 (P < .001 for both). In PACIFIC-1, AI-QCT_{ISCHEMIA} outperformed SPECT in

Abbreviations: AI-QCT, artificial intelligence-based quantitative computed tomography; AI-QCT_{ISCHEMIA}, ischemia model from AI-QCT; AUC, area under the receiving operating curve; CAD, coronary artery disease; CCTA, coronary computed tomography angiography; CMR, cardiac magnetic resonance; FFR, fractional flow reserve; ICA, invasive coronary angiography; MACE, major adverse cardiovascular events; MPI, myocardial perfusion imaging; PET, positron emission tomography; SPECT, single photon emission computed tomography.

Keywords: artificial intelligence; coronary computed tomography angiography; coronary artery disease.

* Corresponding author: p.a.kamila@lumc.nl (P.A. Kamila).

† Co-first authors.

¹ A list of investigators is located at the end of the text.

<https://doi.org/10.1016/j.jscai.2025.104064>

Received 22 July 2025; Received in revised form 13 October 2025; Accepted 14 October 2025; Available online 30 December 2025

2772-9303/© 2025 The Author(s). Published by Elsevier Inc. on behalf of the Society for Cardiovascular Angiography & Interventions Foundation. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

men (AUC = 0.86 vs 0.67; $P < .001$) and women (0.81 vs 0.65; $P < .001$) while performing comparably with PET (0.86 vs 0.82; $P = .140$; 0.81 vs 0.72; $P = .214$). In older patients, AI-QCT_{ISCHEMIA} showed higher performance than SPECT (0.85 vs 0.73; $P < .001$) and was similar to PET (0.85 vs 0.86; $P = .816$). In younger patients, it also outperformed SPECT (0.87 vs 0.66; $P < .001$) with comparable performance with PET (0.87 vs 0.84; $P = .338$).

Conclusions: AI-QCT_{ISCHEMIA} demonstrated consistently high diagnostic performance to detect myocardial ischemia across sex and age groups, significantly outperforming SPECT and showing comparable performance with PET, supporting its role as a noninvasive alternative for ischemia assessment.

Introduction

Personalized strategies for diagnosing coronary artery disease (CAD) have become increasingly important as clinical evidence highlights heterogeneity in disease presentation across populations.¹ Traditionally, myocardial perfusion imaging (MPI) with single-photon emission computed tomography (SPECT) or positron emission tomography (PET) has been the standard for functional assessment; however, these approaches are limited by the lack of anatomical assessment and substantial health care costs.^{2,3} In contrast, coronary computed tomography angiography (CCTA) offers direct visualization of coronary artery anatomy and has achieved a class 1 recommendation as a first-line diagnostic test for suspected CAD, reflecting its growing clinical importance.^{4,5}

The integration of artificial intelligence (AI) in CCTA analysis has further enhanced its diagnostic potential. A novel approach, AI-QCT_{ISCHEMIA} (Clearly, Inc), leverages AI-driven, quantitative analysis from CCTA to predict myocardial ischemia. Prior studies have demonstrated that AI-QCT_{ISCHEMIA} has a high diagnostic accuracy for the detection of reduced fractional flow reserve (FFR), surpassing SPECT.^{6,7} Furthermore, the algorithm has shown strong prognostic value for predicting major adverse cardiovascular events (MACE).⁸

Despite these advancements, the sex- and age-specific diagnostic performance of AI-QCT_{ISCHEMIA} remains insufficiently characterized. Given established differences in the pathophysiology and clinical presentation of CAD between sexes and across age groups,⁹ it is essential to evaluate diagnostic tools within these demographic contexts. This study evaluates the ability of AI-QCT_{ISCHEMIA} to predict ischemia in sex- and age-stratified cohorts, addressing a critical evidence gap and advancing personalized cardiovascular diagnostic assessments.

Materials and methods

Study population

This post-hoc analysis was conducted using data from the computed tomographic evaluation of atherosclerotic determinants of myocardial ischemia (CREDENCE) (NCT02173275) and comparison of CCTA, SPECT, PET, and hybrid imaging for diagnosis of ischemic heart disease determined by FFR (PACIFIC-1) (NCT01521468) trials^{10,11} to assess the accuracy of AI-QCT_{ISCHEMIA} across various demographic subgroups. The CREDENCE trial was a prospective, multicenter study that enrolled 305 patients (868 vessels) from the validation cohort, with stable symptoms without prior diagnosis of CAD. Participants were recruited from 23 centers between 2014 and 2017. The PACIFIC-1 trial, conducted from 2012 to 2014, included 208 patients (612 vessels) with new-onset, stable chest pain and suspected CAD. All participants in both trials underwent invasive coronary angiography (ICA) with 3-vessel FFR measurements, the reference standard for diagnosing ischemia. In addition to ICA and FFR, diagnostic assessments included CCTA and MPI using SPECT and/or PET. Both studies were approved by the local ethics committees, and all participants provided written informed consent. The studies were conducted in accordance with the Declaration of Helsinki.

CCTA acquisition

In both studies, CCTA was performed using single- or dual-source CT scanners with at least 64-detector rows. All images were acquired in accordance with the guidelines provided by the Society of Cardiovascular Computed Tomography.¹²

AI-QCT_{ISCHEMIA} derived from coronary CTA

The CCTA scans from both studies were analyzed using the Food and Drug Administration–cleared AI-QCT algorithm.¹³ This software employs convolutional neural networks, including 3-dimensional U-Net and Visual Geometry Group (VGG) network variants, as described previously.¹⁴ The algorithm performs multiple functions: it assesses image quality, segments and labels coronary arteries, evaluates blood vessel walls, determines vessel contours, and characterizes plaque. The AI-QCT algorithm generates several key quantitative metrics, including stenosis parameters; plaque measures such as total plaque volume, composition-specific volumes, and plaque burden; and vascular morphology, including vessel length, lumen and vessel volume, and average lumen area. It also evaluates the diffuseness of atherosclerosis by summing plaque volumes and lengths across all affected segments.

A predictive model for ischemia detection, AI-QCT_{ISCHEMIA}, was developed using quantitative parameters derived from the AI-QCT algorithm, based on the CREDENCE derivation cohort comprising 307 patients, as described in a previous study.⁷ This model identifies vessel-specific ischemia in a binary manner, defined by an invasive FFR ≤ 0.80 . Model construction was based on AI-QCT measurements and invasive FFR data, with investigators blinded to all clinical, diagnostic, and outcomes information. Vessels with AI-QCT-derived stenosis $< 20\%$ were initially classified as nonischemic, whereas those with stenosis $> 80\%$ were considered ischemic. For vessels falling within the intermediate stenosis range (20%–80%), a machine learning–based predictive model incorporating 37 quantitative features from the AI-QCT algorithm was employed to estimate the likelihood of functionally significant stenosis. A random forest algorithm achieved the highest internal performance in the derivation cohort and was selected as the final model. The final random forest model was constructed with hyperparameter tuning achieved via 10 repeated stratified 5-fold cross-validation. Bayesian hyperparameter optimization was employed to maximize the average performance over the test sets across all random splits and folds. The optimized model comprised over 1000 decision trees, each with a maximal depth of 7 layers.⁷

The diagnostic threshold for AI-QCT_{ISCHEMIA} was selected to optimize the balance between sensitivity and specificity, with a specificity target of > 0.80 at the vessel territory level. A probability cutoff value of 0.31 was established, with values at or above this threshold considered abnormal. The AI-QCT_{ISCHEMIA} model has been tested and externally validated, with its diagnostic performance benchmarked against both invasive and noninvasive modalities in prior studies.^{7,15}

ICA and FFR

Patients underwent diagnostic ICA by board-certified interventional cardiologists in accordance with clinical indications and imaging

standards. In the CREDENCE study, coronary arteries and side branches with a diameter ≥ 2.0 mm and luminal stenosis between 40% and 90% underwent FFR measurements using intracoronary or intravenous adenosine to induce hyperemia. For lesions with less than 40% stenosis, FFR was performed if deemed necessary. The images were then analyzed by an independent, blinded core laboratory for performance of quantitative coronary angiography and FFR reliability. In the PACIFIC-1 study, ICA was performed according to a standardized protocol, including dual orthogonal views for each coronary artery segment. All major coronary arteries were routinely evaluated with FFR, even in patients without visual stenoses, except for occluded or subtotal lesions ($\geq 90\%$). Furthermore, intracoronary (150 μg) or intravenous (140 $\mu\text{g/kg/min}$) adenosine infusion was used to induce maximal coronary hyperemia. Angiographic images and FFR data underwent thorough review by experienced cardiologists, blinded to the noninvasive imaging results. FFR was calculated as the ratio of mean distal intracoronary pressure to mean aortic pressure, with ischemia defined by an FFR value ≤ 0.8 .^{11,16}

MPI acquisition and interpretation

MPI in the CREDENCE study was conducted using either SPECT, PET, or cardiac magnetic resonance (CMR).^{7,10,16} In CREDENCE, interpretation of SPECT and PET images followed the 17-segment model recommended by the American Heart Association (AHA) and American College of Cardiology (ACC), and summed stress scores were computed per coronary artery territory. CMR perfusion imaging was assessed at rest and during stress phases using 16 of the 17 AHA/ACC segments (excluding the apex), with each segment classified as normal (score 0) or abnormal (score 1). These segmental scores were then summed by vascular territory, with an summed stress scores ≥ 1 , denoting abnormal perfusion. In the PACIFIC-1 study,¹¹ patients underwent PET with 370 Mbq of [^{15}O]H₂O at rest and during adenosine-induced hyperemia, with hyperemic myocardial blood flow quantified for all 3 major coronary territories; a value of ≤ 2.30 mL/min/g was considered abnormal. In addition, patients underwent SPECT using a 2-day stress-rest protocol, and summed difference scores were derived from the 17-segment AHA/ACC model to account for vessel territory, with summed difference scores ≥ 2 defined as abnormal.

Statistical analysis

Baseline characteristics were summarized using descriptive statistics, with continuous variables presented as mean $\pm$ SD and categorical variables as frequency and percentage. Group comparisons were conducted using Student t test for continuous variables and the χ^2 test for categorical variables. Subgroup analyses stratified by age and sex were performed to assess diagnostic performance at the per-vessel level. Performance metrics of AI-QCT_{ISCHEMIA}, including sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy, were evaluated against invasive FFR (≤ 0.80) as the reference standard, with additional comparisons made to MPI. Receiver operating characteristic curve analysis was conducted using continuous output values, and the area under the curve (AUC) for each modality was compared with that of AI-QCT_{ISCHEMIA} using the DeLong test. All statistical analyses were performed using SPSS Statistics version 29.0.0.0 (IBM Corp) and R Studio version 4.5.0. A P value $< .05$ was considered statistically significant.

Results

Ischemia detection in men and women

In the CREDENCE study, women demonstrated significantly lower total plaque volume compared with men (164.28 ± 147.86 mm³ vs

227.64 ± 211.09 mm³; $P < .001$), as well as lower overall percent atheroma volume ($16.33\% \pm 11.14\%$ vs $18.26\% \pm 11.82\%$; $P < .05$). In addition, women had significantly less necrotic core volume (1.33 ± 2.16 mm³ vs 1.97 ± 3.86 mm³; $P = .002$), noncalcified plaque volume (104.71 ± 87.65 mm³ vs 151.25 ± 137.76 mm³; $P < .001$), and calcified plaque volume (106.04 ± 88.84 mm³ vs 153.22 ± 139.81 mm³; $P = .02$) compared with men. Women in CREDENCE were also less likely to have obstructive CAD. Similarly, findings from the PACIFIC-1 study revealed that women had significantly lower plaque volume (51.02 ± 81.07 mm³ vs 120.08 ± 151.65 mm³; $P < .001$) and plaque burden ($8.99\% \pm 12.51\%$ vs $17.39\% \pm 16.68\%$; $P < .001$) compared with men. Detailed characteristics are shown in Table 1.

In the CREDENCE study, per-vessel analysis in women demonstrated that AI-QCT_{ISCHEMIA} achieved an AUC of 0.85 (95% CI, 0.79-0.90), which was significantly higher than MPI (AUC = 0.71; 95% CI, 0.63-0.79; $P < .001$). A similar trend was observed in men, where AI-QCT_{ISCHEMIA} yielded an AUC of 0.87 (95% CI, 0.84-0.90), outperforming MPI (AUC = 0.63; 95% CI, 0.58-0.68; $P < .001$; Figure 1A). External validation in the PACIFIC-1 cohort confirmed the consistency of these findings. In women, per-vessel analysis demonstrated that AI-QCT_{ISCHEMIA} maintained superior diagnostic performance compared with SPECT (AUC = 0.81; 95% CI, 0.70-0.92 vs AUC = 0.65, 95% CI, 0.55-0.75; $P < .001$), whereas showing comparable performance with PET (AUC = 0.72; 95% CI, 0.58-0.86; $P = .214$). A similar pattern was observed in men, where AI-QCT_{ISCHEMIA} achieved an AUC of 0.86 (95% CI, 0.83-0.90), superior to SPECT (AUC = 0.67; 95% CI, 0.61-0.73; $P < .001$) and comparable with PET (AUC = 0.82; 95% CI, 0.78-0.87; $P = .140$) (Figure 2A). The detailed diagnostic performance metrics (sensitivity, specificity, NPV, and PPV) are summarized in Table 3 and Table 4.

Ischemia detection in older versus younger patients

In the CREDENCE cohort, patients aged ≥ 65 years exhibited significantly greater calcified plaque volume compared with their younger counterparts (279.09 ± 310.10 mm³ vs 149.26 ± 194.96 mm³, $P < .001$), as well as a higher total plaque volume (223.06 ± 213.35 mm³, $P = .01$) and overall plaque burden ($19.48\% \pm 12.48\%$ vs $15.64\% \pm 10.28\%$, $P < .001$). Although younger individuals showed a trend toward higher noncalcified plaque volume, the difference was not statistically significant (140.59 ± 130.34 mm³ vs 133.02 ± 122.00 mm³, $P = .38$). A similar pattern was observed in the PACIFIC-1 cohort, where older patients (≥ 65 years) had significantly greater total plaque volume (123.30 ± 146.50 mm³ vs 85.42 ± 128.90 mm³, $P < .001$) and plaque burden ($18.52\% \pm 17.87\%$ vs $12.94\% \pm 14.84\%$, $P < .001$). Calcified plaque volume was also significantly higher in the older group (69.08 ± 101.12 mm³ vs 35.76 ± 66.60 mm³, $P < .001$). No significant difference was observed in noncalcified plaque volume between age groups (53.46 ± 56.20 mm³ vs 48.40 ± 78.33 mm³, $P = .44$). Detailed characteristics are summarized in Table 2.

AI-QCT_{ISCHEMIA} demonstrated consistent performance across age groups. In the CREDENCE cohort, per-vessel analysis showed that in the older population, AI-QCT_{ISCHEMIA} achieved an AUC of 0.85 (95% CI, 0.81-0.89), significantly higher than MPI (AUC = 0.67; 95% CI, 0.61-0.73; $P < .001$). Similarly, in the younger population, AI-QCT_{ISCHEMIA} had an AUC of 0.87 (95% CI, 0.83-0.91), surpassing MPI (AUC = 0.63; 95% CI, 0.56-0.70; $P < .001$) (Figure 1B). In the PACIFIC-1 study, among older individuals, AI-QCT_{ISCHEMIA} showed an AUC of 0.85 (95% CI, 0.78-0.91), significantly higher than SPECT (AUC = 0.73; 95% CI, 0.63-0.83; $P = .008$) and comparable with PET (AUC = 0.86; 95% CI, 0.79-0.93; $P = .814$). In the younger cohort, AI-QCT_{ISCHEMIA} had an AUC of 0.87 (95% CI, 0.83-0.91), outperforming SPECT (AUC = 0.66; 95% CI, 0.60-0.72; $P < .001$) and showing similar performance to PET (AUC = 0.84; 95% CI, 0.80-0.88; $P = .338$) (Figure 2B). Details on sensitivity, specificity, NPV, and PPV are provided in Tables 3 and 4.

Table 1. Per-vessel baseline characteristics by sex in CREDENCE and PACIFIC-1 studies.

Characteristics	CREDENCE			PACIFIC-1		
	Women (273 vessels)	Men (595 vessels)	P value	Women (226 vessels)	Men (386 vessels)	P value
Total plaque volume, mm ³	164.28 ± 147.86	227.64 ± 211.09	<.001	51.02 ± 81.07	120.08 ± 151.65	<.001
Low density plaque volume, mm ³	1.33 ± 2.16	1.97 ± 3.86	.002	0.13 ± 0.069	1.73 ± 7.28	<.001
Noncalcified plaque volume, mm ³	104.71 ± 87.65	151.25 ± 137.76	<.001	23.28 ± 34.52	65.04 ± 80.16	<.001
Calcified plaque volume, mm ³	106.04 ± 88.84	153.22 ± 139.81	.021	27.61 ± 53.98	53.31 ± 87.26	<.001
PAV (total), %	16.33 ± 11.14	18.26 ± 11.82	.021	8.99 ± 12.51	17.39 ± 16.68	<.001
PAV CP, %	5.60 ± 7.08	6.01 ± 7.67	.453	4.89 ± 8.82	7.70 ± 10.35	<.001
PAV NCP, %	10.59 ± 6.63	12.09 ± 7.37	.004	4.07 ± 5.07	9.47 ± 8.57	<.001
Average lumen area, mm ²	3.98 ± 1.21	4.17 ± 1.40	.038	4.09 ± 1.74	4.62 ± 2.25	.001
Diameter stenosis, %	35.55 ± 24.19	40.57 ± 24.44	.005	17.85 ± 22.32	34.21 ± 30.31	<.001
0%	7 (2.6%)	9 (1.5%)	.009	59 (26.1%)	49 (12.7%)	<.001
1%-24%	97 (35.5%)	175 (29.4%)		105 (46.5%)	142 (36.8%)	
25%-49%	104 (38.1%)	210 (35.3%)		33 (14.6%)	63 (16.3%)	
50%-69%	32 (11.7%)	110 (18.5%)		15 (6.6%)	59 (15.3%)	
70%-99%	21 (7.7%)	61 (10.3%)		12 (5.3%)	57 (14.8%)	
100%	12 (4.4%)	30 (5.0%)		2 (0.9%)	16 (4.1%)	
Prevalence of ischemia (FFR ≤0.80)	67 (24.5%)	162 (27.2%)	.405	21 (9.3%)	144 (37.3%)	<.001

Values are mean ± SD or n (%).
CP, calcified plaque; FFR, fractional flow reserve; NCP, noncalcified plaque; PAV, percent atheroma volume.

Discussion

In this study, we evaluated the diagnostic performance of a novel AI-guided quantitative coronary computed tomography algorithm, AI-QCT_{ISCHEMIA}, for predicting myocardial ischemia across key demographic subgroups. The principal finding is that the algorithm demonstrated consistently high diagnostic accuracy in both men and

women, as well as in younger and older patients, with improved performance compared with standard nuclear imaging techniques such as MPI (Central Illustration). The robustness of AI-QCT_{ISCHEMIA} across 2 independent cohorts, despite notable baseline differences in atherosclerotic plaque characteristics among these subgroups, supports its potential utility as a reliable noninvasive tool for diagnosing hemodynamically significant CAD.





Figure 1. Diagnostic Performance of AI-QCT_{ISCHEMIA} by Sex and Age group in CREDENCE. (A) Comparison of AUCs for AI-QCT_{ISCHEMIA} (orange) and MPI (green) in women and men. (B) Comparison of AUCs for AI-QCT_{ISCHEMIA} and MPI in patients aged <65 years and ≥65 years. AI-QCT_{ISCHEMIA} showed significantly improved diagnostic performance compared with MPI in all subgroups (P < .001). AUC, area under the curve; MPI, myocardial perfusion imaging.

**Figure 2.**

Diagnostic performance of AI-QCT_{ISCHEMIA} by Sex and Age groups in PACIFIC-1. (A) Comparison of AUCs for AI-QCT_{ISCHEMIA} (orange), SPECT (blue), and PET (green) in women and men from the PACIFIC-1 study population. (B) Comparison of AUCs for AI-QCT_{ISCHEMIA} (orange), SPECT (blue), and PET (green) in patients aged <65 years and ≥65 years from the PACIFIC-1 study population. AI-QCT_{ISCHEMIA} achieved significantly higher diagnostic performance than SPECT across all subgroups ($P < .05$) and demonstrated comparable performance to PET. AUC, area under the curve; PET, positron emission tomography; SPECT, single-photon emission computed tomography.

Diagnostic performance of AI-QCT_{ISCHEMIA} in men versus women

Consistent with prior literature,^{2,17} men in our study exhibited a higher prevalence of ischemia, lower FFR values, and greater plaque burden compared with women. These findings emphasize the importance of incorporating sex-specific considerations when evaluating diagnostic tools, particularly for women, who often present with unique disease manifestations. Unlike men, women tend to have a higher prevalence of nonobstructive stenosis and a tendency to present at an older age and/or with atypical

symptoms.^{18,19} However, traditional diagnostic modalities are often suboptimal in women due to anatomical and physiological differences.¹⁷ These challenges can result in delayed or missed diagnoses, although women with ischemia have similar or even greater risks of adverse outcomes and diminished quality of life as compared with men.²⁰ This diagnostic gap highlights a critical unmet need for more tailored noninvasive strategies that maintain accuracy across sexes.

In our study, AI-QCT_{ISCHEMIA} demonstrated high diagnostic accuracy in both sexes across both cohorts, compared with SPECT.

Table 2. Per-vessel baseline characteristics by age groups in CREDENCE and PACIFIC-1 studies.

Characteristics	CREDENCE			PACIFIC-1		
	Age <65 years (412 vessels)	Age ≥65 years (456 vessels)	P value	Age <65 years (464 vessels)	Age ≥65 years (148 vessels)	P value
Total plaque volume, mm ³	190.72 ± 172.50	223.06 ± 213.35	.014	85.42 ± 128.93	123.30 ± 146.50	.001
Low density plaque volume, mm ³	2.14 ± 4.29	1.44 ± 2.36	.003	1.26 ± 6.50	0.76 ± 2.98	.366
Noncalcified plaque volume, mm ³	140.59 ± 130.34	133.02 ± 122.0	.377	48.40 ± 78.33	53.46 ± 56.20	.444
Calcified plaque volume, mm ³	47.99 ± 75.82	88.61 ± 124.27	<.001	35.76 ± 66.60	69.08 ± 101.12	<.001
PAV (total), %	15.64 ± 10.28	19.48 ± 12.48	<.001	12.94 ± 14.84	18.52 ± 17.87	<.001
PAV CP, %	3.99 ± 5.74	7.60 ± 8.43	<.001	5.50 ± 8.48	10.30 ± 12.77	<.001
PAV NCP, %	11.47 ± 7.28	11.75 ± 7.09	.576	7.27 ± 8.16	8.13 ± 7.04	.217
Average lumen area, mm ²	4.28 ± 1.37	3.95 ± 1.29	<.001	4.48 ± 2.05	4.24 ± 2.21	.225
Diameter stenosis, %	37.30 ± 24.19	40.53 ± 24.63	.052	25.97 ± 28.02	35.06 ± 29.86	<.001
0%	8 (1.9%)	8 (1.8%)	.179	95 (20.5%)	13 (8.8%)	<.001
1%-24%	143 (34.7%)	129 (28.3%)		192 (41.4%)	55 (37.2%)	
25%-49%	148 (35.9%)	166 (36.4%)		65 (14%)	31 (20.9%)	
50%-69%	55 (13.3%)	87 (19.1%)		54 (11.6%)	20 (13.5%)	
70%-99%	41 (10%)	41 (9.0%)		48 (10.3%)	21 (14.2%)	
100%	17 (4.1%)	25 (5.5%)		10 (2.2%)	8 (5.4%)	
Prevalence of ischemia (FFR ≤0.80)	100 (24.3%)	129 (28.3%)	.063	120 (25.9%)	45 (30.4%)	.292

Values are mean ± SD or n (%).

CP, calcified plaque; FFR, fractional flow reserve; NCP, noncalcified plaque; PAV, percent atheroma volume.

Table 3. Diagnostic metrics of AI-QCT_{ISCHEMIA} compared with MPI in the CREDENCE study population.

Test	Sensitivity	Specificity	PPV	NPV	Accuracy
CREDENCE: women (273 vessels)					
AI-QCT _{ISCHEMIA}	71.6% (48/67)	87.9% (181/206)	65.8% (48/73)	90.5% (181/200)	83.9% (229/273)
MPI	65.7% (44/67)	68.0% (140/206)	40.0% (44/110)	85.9% (140/163)	67.4% (184/273)
CREDENCE: men (595 vessels)					
AI-QCT _{ISCHEMIA}	79.0% (128/162)	78.5% (340/433)	57.9% (128/221)	90.9% (340/374)	78.7% (468/595)
MPI	55.6% (90/162)	64.2% (278/433)	36.7% (90/245)	79.4% (278/350)	61.8% (369/595)
CREDENCE: ≥65 years old (456 vessels)					
AI-QCT _{ISCHEMIA}	77.5% (100/129)	79.2% (259/327)	59.5% (100/168)	89.9% (259/288)	78.7% (359/456)
MPI	62.0% (82/129)	66.7% (218/267)	42.3% (80/189)	81.6% (218/267)	65.4% (298/456)
CREDENCE: <65 years old (412 vessels)					
AI-QCT _{ISCHEMIA}	76.0% (76/100)	84.0% (262/312)	60.3% (76/126)	91.6% (262/286)	82.0% (338/412)
MPI	54.0% (54/100)	64.1% (200/312)	32.5% (54/166)	81.3% (200/246)	61.7% (254/412)

Values are % (n/N).

MPI, myocardial perfusion imaging.

Although MPI remain valuable noninvasive tools, its diagnostic performance may be influenced by sex-specific anatomical and physiological factors.^{21,22} For instance, SPECT imaging has limitations in women due to the smaller heart size, which potentially reduces sensitivity for detecting obstructive CAD; also, breast attenuation may result in false-positive SPECT results.^{23,24} In addition, AI-QCT_{ISCHEMIA} performed comparably to PET in both sexes, supporting its role as a balanced diagnostic tool across sex-specific disease profiles.

Although AI-QCT_{ISCHEMIA} provides reliable diagnostic performance in both men and women, subtle sex-specific differences were observed. In women, the algorithm yielded slightly lower sensitivity but higher specificity and notably high NPV, making it a particularly valuable rule-out tool in clinical settings where diagnostic uncertainty is common. In men, the model exhibited slightly higher sensitivity with comparable specificity, underscoring its effectiveness in detecting ischemia, which is more prevalent in this group. Importantly, these subtle variations did not result in a statistically significant difference in overall diagnostic performance, confirming the algorithm's strong and balanced performance profile across both sexes.

The diagnostic strength of AI-QCT_{ISCHEMIA} aligns with prior studies, suggesting that AI-based diagnostic tools provide improved accuracy compared with traditional methods such as MPI.^{15,25,26} The model's high performance likely stems from its multiparametric analytical framework, which integrates 37 AI-derived quantitative parameters, including stenosis severity, plaque characteristics, and vascular morphology,⁷ enabling precise ischemia detection. This integrative approach suggests that AI-QCT_{ISCHEMIA} may serve as a reliable, sex-inclusive alternative for myocardial ischemia assessment.

Diagnostic performance of AI-QCT_{ISCHEMIA} across different age groups

The current study also highlighted distinct age-related patterns in coronary artery pathology: older patients demonstrated higher ischemia prevalence, greater plaque burden, and more calcified plaques, whereas younger individuals showed predominance of non-calcified plaques, aligning with previous findings.^{27–30} Despite these differences, AI-QCT_{ISCHEMIA} maintained high diagnostic performance across all age groups, significantly outperforming SPECT and showing comparable performance with PET.

The superior performance of AI-QCT_{ISCHEMIA} in older adults is particularly noteworthy, given the high prevalence and complexity of CAD in the elderly, where precise diagnostic tools are critical for effective clinical management.³¹ Importantly, its diagnostic strength also extended to younger patients, who typically present with lower disease prevalence and different clinical profiles. Accurate ischemia detection in younger individuals is clinically important, as it enables timely identification of functionally significant coronary disease and may inform early therapeutic decisions that prevent progression and adverse cardiac events. These observations support the potential applicability of AI-QCT_{ISCHEMIA} as a noninvasive diagnostic method suitable across a broad age spectrum.

The improved diagnostic performance of AI-QCT_{ISCHEMIA} relative to conventional modalities stems from its machine learning architecture, which mitigates some limitations of existing noninvasive ischemia testing.^{15,25,32} Moreover, it may offer advantages in situations where conventional MPI is less informative due to technical or


Table 4. Diagnostic metrics of AI-QCT_{ISCHEMIA} compared with SPECT and PET in the PACIFIC-1 study population.

Test	Sensitivity	Specificity	PPV	NPV	Accuracy
PACIFIC-1: women (226 vessels)					
AI-QCT _{ISCHEMIA}	66.7% (14/21)	88.3% (181/205)	36.8% (14/38)	96.3% (181/188)	86.3% (195/226)
SPECT	33.3% (7/21)	96.6% (198/205)	50.0% (7/14)	93.4% (198/212)	90.7% (205/226)
PET	47.6% (10/21)	91.7% (188/205)	37.0% (10/27)	94.5% (188/199)	87.6% (198/226)
PACIFIC-1: men (386 vessels)					
AI-QCT _{ISCHEMIA}	77.1% (111/144)	80.6% (195/242)	70.3% (111/158)	85.5% (195/228)	79.3% (306/386)
SPECT	42.4% (61/144)	88.8% (215/242)	69.3% (61/88)	72.1% (215/298)	71.5% (276/386)
PET	86.1% (124/144)	66.9% (162/242)	60.8% (124/204)	89.0% (162/182)	74.1% (286/386)
PACIFIC-1: ≥65 years old (148 vessels)					
AI-QCT _{ISCHEMIA}	80% (36/45)	76.7% (79/103)	60.0% (36/60)	89.8% (79/88)	77.7% (115/148)
SPECT	48.9% (22/45)	91.3% (94/103)	71.0% (22/31)	80.3% (94/117)	78.4% (116/148)
PET	86.7% (39/45)	72.8% (75/103)	58.2% (39/67)	92.6% (75/81)	77.0% (114/148)
PACIFIC-1: <65 years old (464 vessels)					
AI-QCT _{ISCHEMIA}	74.2% (89/120)	86.3% (297/344)	65.4% (89/136)	90.5% (297/328)	83.2% (386/464)
SPECT	38.3% (46/120)	92.7% (319/344)	64.8% (46/71)	81.2% (319/393)	78.7% (365/464)
PET	79.2% (95/120)	79.9% (275/344)	57.9% (95/164)	91.7% (275/300)	79.7% (370/464)

Values are % (n/N).

PET, positron emission tomography; SPECT, single-photon emission computed tomography.

CENTRAL ILLUSTRATION: Diagnostic performance of a novel artificial intelligence-guided coronary computed tomography algorithm for predicting myocardial ischemia (AI-QCT_{ISCHEMIA}) across sex and age subgroups



Central Illustration.

Diagnostic performance of AI-QCT_{ISCHEMIA} for vessel-specific coronary ischemia across sex and age subgroups. Receiver operating characteristic curve analyses demonstrated consistently high diagnostic performance of AI-QCT_{ISCHEMIA} across sex and age subgroups, outperforming SPECT and showing comparable performance to PET. These findings highlight the potential AI-QCT_{ISCHEMIA} as a reliable noninvasive approach for ischemia detection.

patient-specific limitations.³³ In PACIFIC-1, [¹⁵O]H₂O PET was used, regarded as the “gold standard” method for absolute measurement of myocardial blood flow, although its broader clinical use is constrained by limited availability.^{34,35} The comparable performance of AI-QCT_{ISCHEMIA} against PET in this study supports its potential role

as a practical and scalable alternative, particularly where PET is not routinely accessible. These findings suggest that AI-QCT_{ISCHEMIA} may complement existing modalities by enhancing diagnostic consistency and reliability across a broad range of anatomical and clinical scenarios.

Clinical Integration of AI-QCT_{ISCHEMIA}

The consistent diagnostic accuracy of AI-QCT_{ISCHEMIA} across sex and age subgroups supports its potential for integration into routine clinical workflows. Using quantitative parameters obtainable from standard CCTA, the algorithm may help reduce diagnostic uncertainty, minimize the need for additional functional testing, and broaden the role of CCTA beyond purely anatomical assessment. Our findings show that an AI-guided CCTA algorithm can predict functionally significant ischemia directly from anatomical features, making it a comprehensive tool that combines the assessment of stenosis, plaque burden, and ischemia in a single test. Refinement at the coronary segment level could further increase its clinical value, particularly in revascularization planning.

Limitations

This study has several limitations. Since this is a post-hoc analysis of 2 multicenter trials, there is a potential for selection bias, which may affect the generalizability of the findings to wider patient populations. Moreover, although combining data from the CREDENCE and PACIFIC-1 cohorts enhanced the sample size and diversity, inherent differences in study design, patient characteristics, and imaging protocols may have introduced some variability in the results. Ischemia prediction was evaluated at the vessel level, whereas segment level assessment (eg, proximal vs distal segments) was beyond the scope of this study but may provide additional procedural insights and warrants investigation in future studies. Finally, although this study focused on diagnostic accuracy, future investigations should explore clinical outcomes, cost-effectiveness, and workflow integration to better define its role in practice.

Conclusion

The AI-QCT_{ISCHEMIA} demonstrates high diagnostic performance for the detection of myocardial ischemia, significantly outperforming standard nuclear perfusion imaging, such as SPECT, and showing comparable performance with PET across sex and age subgroups. By leveraging comprehensive AI-driven quantitative parameters, AI-QCT_{ISCHEMIA} offers a more precise assessment across various patient demographic characteristics. These findings suggest that AI-QCT_{ISCHEMIA} may contribute to reducing diagnostic uncertainty and enhancing timely, informed clinical decision making across a broad range of patients. Future prospective studies are warranted to evaluate its role in guiding therapy and improving clinical outcomes.

The CREDENCE and PACIFIC-1 investigators

Ran Heo, MD, PhD¹, Hyung-Bok Park, MD², Hugo Marques, MD, PhD³, Wijnand J. Stuijtzand, MD, PhD⁴, Jung Hyun Choi, MD, PhD⁵, Joon-Hyung Doh, MD⁶, Ae-Young Her, MD, PhD⁷, Bon-Kwon Koo, MD, PhD⁸, Chang-Wook Nam, MD, PhD⁹, Sang-Hoon Shin, MD¹⁰, Jason Cole, MD¹¹, Alessia Gimelli, MD¹², Muhammad Akram Khan, MD¹³, Bin Lu, MD¹⁴, Yang Gao, MD¹⁴, Faisal Nabi, MD¹⁵, Mouaz H. Al-Mallah, MD¹⁵, Ryo Nakazato, MD¹⁶, U. Joseph Schoepf, MD¹⁷, Randall C. Thompson, MD¹⁸, James J. Jang, MD¹⁹, Michael Ridner, MD²⁰, Chris Rowan, MD²¹, Erick Avelar, MD²², Philippe G  n  reux, MD²³, Guus A. de Waard, MD⁴

¹Division of Cardiology, Department of Internal Medicine, Hanyang University Medical Center, Seoul, South Korea; ²Division of Cardiology, Department of Internal Medicine, International St. Mary's Hospital, Catholic Kwandong University College of Medicine, Incheon, South Korea; ³Faculdade de Medicina da Universidade Cat  lica Portuguesa, Lisboa, Portugal; ⁴Department of Cardiology, Amsterdam UMC, Vrije

Universiteit Amsterdam, Amsterdam, the Netherlands; ⁵Department of Cardiology, Pusan National University Hospital, Busan, South Korea; ⁶Division of Cardiology, Inje University Ilsan Paik Hospital, South Korea; ⁷Division of Cardiology, Department of Internal Medicine, Kangwon National University, College of Medicine, Kangwon National University School of Medicine, Chuncheon, South Korea; ⁸Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea; ⁹Cardiovascular Center, Keimyung University Dongsan Hospital, Daegu, South Korea; ¹⁰Division of Cardiology, Department of Internal Medicine, Ewha Women's University Seoul Hospital, Seoul, South Korea; ¹¹Mobile Cardiology Associates, Mobile, Alabama; ¹²Department of Imaging, Fondazione Toscana Gabriele Monasterio, Pisa, Italy; ¹³Cardiac Center of Texas, McKinney, Texas; ¹⁴State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, Beijing, China; ¹⁵Houston Methodist Hospital, Houston, Texas; ¹⁶Cardiovascular Center, St. Luke's International Hospital, Tokyo, Japan; ¹⁷Medical University of South Carolina, Charleston, South Carolina; ¹⁸Saint Luke's Mid America Heart Institute, Kansas City, Missouri; ¹⁹San Jose Medical Center, Kaiser Permanente, San Jose, California; ²⁰University of Alabama-Birmingham, Birmingham, Alabama; ²¹University of Wisconsin-Madison, Madison, Wisconsin; ²²Oconee Heart and Vascular Center, University of Georgia School of Medicine, Athens, Georgia; ²³Morristown Medical Center, Morristown, New Jersey

Declaration of competing interest

Gianluca Pontone received an honorarium as a speaker/consultant and an institutional research grant from GE Healthcare, Bracco, Medtronic, and Novartis. Ibrahim Danad is a member of the Cleerly Scientific Advisory Board. Nick S. Nurmohamed reports grants from the Dutch Heart Foundation (Dekker 03-007-2023-0068), European Atherosclerosis Society (2023), research funding/speaker fees from Cleerly, Daiichi Sankyo, and Novartis, and is co-founder of Lipid Tools. Alexander van Rosendaal is a member of the Cleerly Scientific Advisory Board. The remaining authors have no conflicts of interest to declare.

Funding sources

This work was not supported by funding agencies in the public, commercial, or not-for-profit sectors.

Ethics statement and patient consent

This study is a post-hoc substudy of the CREDENCE (NCT02173275) and PACIFIC-1 (NCT01521468) trials. Both trials were approved by the local institutional review boards, and all participants provided written informed consent at the time of enrollment.

Declaration of Generative AI and AI-Assisted Technologies in the Writing Process

During the preparation of this work the authors used ChatGPT 5.0 (OpenAI) in order to detect grammatical errors. After using this tool, the authors reviewed and edited the content as needed and take full responsibility for the content of the publication.

References

- Bamba H, Singh G, John J, et al. Precision medicine approaches in cardiology and personalized therapies for improved patient outcomes: a systematic review. *Curr Prob Cardiol*. 2024;49(5):102470. <https://doi.org/10.1016/j.cpcardiol.2024.102470>
- Gulati M, Levy PD, Mukherjee D, et al. 2021 AHA/ACC/AASE/CHEST/SAEM/SCCT/SCMR guideline for the evaluation and diagnosis of chest pain: a report of the American College of Cardiology/American Heart Association Joint Committee

- on clinical practice guidelines. *J Am Coll Cardiol*. 2021;78(22):e187–e285. <https://doi.org/10.1016/j.jacc.2021.07.053>
3. Einstein AJ, Berman DS, Min JK, et al. Patient-centered imaging: shared decision making for cardiac imaging procedures with exposure to ionizing radiation. *J Am Coll Cardiol*. 2014;63(15):1480–1489. <https://doi.org/10.1016/j.jacc.2013.10.092>
 4. Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. *Eur Heart J*. 2020;41(3):407–477. <https://doi.org/10.1093/eurheartj/ehz425>
 5. Nurmohamed NS, van Rosendaal AR, Danad I, et al. Atherosclerosis evaluation and cardiovascular risk estimation using coronary computed tomography angiography. *Eur Heart J*. 2024;45(20):1783–1800. <https://doi.org/10.1093/eurheartj/ehae190>
 6. Lipkin I, Telluri A, Kim Y, et al. Coronary CTA With AI-QCT interpretation: comparison with myocardial perfusion imaging for detection of obstructive stenosis using invasive angiography as reference standard. *AJR Am J Roentgenol*. 2022;219(3):407–419. <https://doi.org/10.2214/AJR.21.27289>
 7. Nurmohamed NS, Danad I, Jukema RA, et al. Development and validation of a quantitative coronary CT angiography model for diagnosis of vessel-specific coronary ischemia. *JACC Cardiovasc Imaging*. 2024;17(8):894–906. <https://doi.org/10.1016/j.jcmg.2024.01.007>
 8. Bär S, Nabeta T, Maanittu T, et al. Prognostic value of a novel artificial intelligence-based coronary computed tomography angiography-derived ischaemia algorithm for patients with suspected coronary artery disease. *Eur Heart J Cardiovasc Imaging*. 2024;25(5):657–667. <https://doi.org/10.1093/ehjci/jead339>
 9. Rodriguez Lozano PF, Rrapo Kaso E, Bourque JM, et al. Cardiovascular imaging for ischemic heart disease in women. *JACC Cardiovascular Imaging*. 2022;15(8):1488–1501. <https://doi.org/10.1016/j.jcmg.2022.01.006>
 10. Stuijzand WJ, van Rosendaal AR, Lin FY, et al. Stress myocardial perfusion imaging vs coronary computed tomographic angiography for diagnosis of invasive vessel-specific coronary physiology: predictive modeling results from the computed tomographic evaluation of atherosclerotic determinants of myocardial ischemia (CREDENCE) trial. *JAMA Cardiol*. 2020;5(12):1338–1348. <https://doi.org/10.1001/jamacardio.2020.3409>
 11. Danad I, Raijmakers PG, Driessen RS, et al. Comparison of coronary CT angiography, SPECT, PET, and hybrid imaging for diagnosis of ischemic heart disease determined by fractional flow reserve. *JAMA Cardiol*. 2017;2(10):1100–1107. <https://doi.org/10.1001/jamacardio.2017.2471>
 12. Leipsic J, Abbara S, Achenbach S, et al. SCCT guidelines for the interpretation and reporting of coronary CT angiography: a report of the Society of Cardiovascular Computed Tomography Guidelines Committee. *J Cardiovasc Comput Tomogr*. 2014;8(5):342–358. <https://doi.org/10.1016/j.jcct.2014.07.003>
 13. Administration USFaD. Cleerly Labs. 510 (k) Premarket Notification; 2019.
 14. Choi AD, Marques H, Kumar V, et al. CT evaluation by artificial intelligence for atherosclerosis, stenosis and vascular morphology (CLARIFY): a multi-center, international study. *J Cardiovasc Comput Tomogr*. 2021;15(6):470–476. <https://doi.org/10.1016/j.jcct.2021.05.004>
 15. Nurmohamed Nick S, Danad I, et al. High diagnostic accuracy of ai-ischemia in comparison to pet, FFR-CT, SPECT, and invasive FFR: a pacific sub-study. *J Am Coll Cardiol*. 2023;81(8 suppl):1362.
 16. Rizvi A, Hartaigh B, Knaepen P, et al. Rationale and design of the CREDENCE trial: computed tomographic evaluation of atherosclerotic DEterminants of myocardial IsChEmia. *BMC Cardiovasc Disord*. 2016;16(1):190. <https://doi.org/10.1186/s12872-016-0360-x>
 17. Aggarwal NR, Patel HN, Mehta LS, et al. Sex differences in ischemic heart disease: advances, obstacles, and next steps. *Circ Cardiovasc Qual Outcomes*. 2018;11(2):e004437. <https://doi.org/10.1161/CIRCOUTCOMES.117.004437>
 18. Kim HL. Sex differences in coronary atherogenesis: a narrative review. *Ewha Med J*. 2024;47(2):e15. <https://doi.org/10.12771/emj.2024.e15>
 19. La S, Beltrame J, Tavella R. Sex-specific and ethnicity-specific differences in MINOCA. *Nat Rev Cardiol*. 2024;21(3):192–202. <https://doi.org/10.1038/s41569-023-00927-6>
 20. Majidi M, Eslami V, Ghorbani P, Foroughi M. Are women more susceptible to ischemic heart disease compared to men? A literature overview. *J Geriatr Cardiol*. 2021;18(4):289–296. <https://doi.org/10.11909/j.issn.1671-5411.2021.04.004>
 21. Fairbairn TA, Dobson R, Hurwitz-Koweek L, et al. Sex differences in coronary computed tomography angiography-derived fractional flow reserve: lessons from ADVANCE. *JACC Cardiovasc Imaging*. 2020;13(12):2576–2587. <https://doi.org/10.1016/j.jcmg.2020.07.008>
 22. Dolor RJ, Patel MR, Melloni C, et al. *AHRQ Comparative Effectiveness Reviews. Noninvasive Technologies for the Diagnosis of Coronary Artery Disease in Women*. Rockville, MD: Agency for Healthcare Research and Quality; 2012.
 23. Hansen CL, Crabbe D, Rubin S. Lower diagnostic accuracy of thallium-201 SPECT myocardial perfusion imaging in women: An effect of smaller chamber size. *J Am Coll Cardiol*. 1996;28(5):1214–1219. [https://doi.org/10.1016/S0735-1097\(96\)00304-X](https://doi.org/10.1016/S0735-1097(96)00304-X)
 24. Taqueti VR, Dorbala S, Wolinsky D, et al. Myocardial perfusion imaging in women for the evaluation of stable ischemic heart disease—state-of-the-evidence and clinical recommendations. *J Nucl Cardiol*. 2017;24(4):1402–1426. <https://doi.org/10.1007/s12350-017-0926-8>
 25. Cho GW, Sayed S, D'Costa Z, Karlsberg DW, Karlsberg RP. First comparison between artificial intelligence-guided coronary computed tomography angiography versus single-photon emission computed tomography testing for ischemia in clinical practice. *Coron Artery Dis*. 2024;36(5):390–395. <https://doi.org/10.1097/MCA.0000000000001485>
 26. Karlsberg RP, Nurmohamed NS, Quesad CG, et al. Performance of an artificial intelligence-guided quantitative coronary computed tomography algorithm for predicting myocardial ischemia in real-world practice. *Int J Cardiol Heart Vasc*. 2024;53:101433. <https://doi.org/10.1016/j.ijcha.2024.101433>
 27. Sheppard JP, Lakshmanan S, Lichtenstein SJ, Budoff MJ, Roy SK. Age and the power of zero CAC in cardiac risk assessment: overview of the literature and a cautionary case. *Br J Cardiol*. 2022;29(3):23. <https://doi.org/10.5837/bjc.2022.023>
 28. Mortensen MB, Gaur S, Frimmer A, et al. Association of age with the diagnostic value of coronary artery calcium score for ruling out coronary stenosis in symptomatic patients. *JAMA Cardiol*. 2022;7(1):36–44. <https://doi.org/10.1001/jamacardio.2021.4406>
 29. Kral BG, Becker LC, Vaidya D, et al. Noncalcified coronary plaque volumes in healthy people with a family history of early onset coronary artery disease. *Circ Cardiovasc Imaging*. 2014;7(3):446–453. <https://doi.org/10.1161/CIRCIMAGING.113.000980>
 30. Jonas R, Earls J, Marques H, et al. Relationship of age, atherosclerosis and angiographic stenosis using artificial intelligence. *Open Heart*. 2021;8(2):e001832. <https://doi.org/10.1136/openhrt-2021-001832>
 31. Cacciatori S, Spadafora L, Bernardi M, et al. Management of coronary artery disease in older adults: recent advances and gaps in evidence. *J Clin Med*. 2023;12(16):5233. <https://doi.org/10.3390/jcm12165233>
 32. Chiou A, Hermel M, Sidhu R, et al. Artificial intelligence coronary computed tomography, coronary computed tomography angiography using fractional flow reserve, and physician visual interpretation in the per-vessel prediction of abnormal invasive adenosine fractional flow reserve. *Eur Heart J Imaging Methods Practice*. 2024;2(1):qyae035. <https://doi.org/10.1093/ehjimp/qyae035>
 33. Chen CC, Chen CC, Hsieh IC, et al. The effect of calcium score on the diagnostic accuracy of coronary computed tomography angiography. *Int J Cardiovasc Imaging*. 2011;27(Suppl 1):37–42. <https://doi.org/10.1007/s10554-011-9955-6>
 34. Lammertsma AA. Accurate quantification of myocardial perfusion. *J Nucl Cardiol*. 2022;29(4):1973–1975. <https://doi.org/10.1007/s12350-021-02703-w>
 35. Manabe O, Naya M, Aikawa T, Yoshinaga K. 15O-labeled water is the best myocardial blood flow tracer for precise MBF quantification. *Ann Nucl Cardiol*. 2019;5(1):69–72. <https://doi.org/10.17996/anc.18-00064>